Abstract
Background Genome-wide association studies have discovered hundreds of common genetic variants for atherosclerotic disease and cardiovascular risk factors. The translation of susceptibility loci into biological mechanisms and targets for drug discovery remains challenging. Intersecting genetic and gene expression data has led to the identification of candidate genes. However, previously studied tissues are often non-diseased and heterogeneous in cell composition, hindering accurate candidate prioritization. Therefore, we analyzed single-cell transcriptomics from atherosclerotic plaques for cell-type-specific expression to identify atherosclerosis-associated candidate gene-cell pairs.
Methods and Results To identify disease-associated genes, we applied gene-based analyses using GWAS summary statistics from 46 atherosclerotic and cardiovascular disease, risk factors, and other traits. We then intersected these candidates with scRNA-seq data to identify genes specific for individual cell (sub)populations in atherosclerotic plaques. The coronary artery disease loci demonstrated a prominent signal in plaque smooth muscle cells (SKI, KANK2, SORT1) p-adj. = 0.0012, and endothelial cells (SLC44A1, ATP2B1) p-adj. = 0.0011. Further sub clustering revealed genes in risk loci for coronary calcification specifically enriched in a synthetic smooth muscle cell population. Finally, we used liver-derived scRNA-seq data and showed hepatocyte-specific enrichment of genes involved in serum lipid levels.
Conclusion We discovered novel gene-cell pairs, on top of known pairs, pointing to new biological mechanisms of atherosclerotic disease. We highlight that loci associated with coronary artery disease reveal prominent association levels in mainly plaque smooth muscle and endothelial cell populations. We present an intuitive single-cell transcriptomics-driven workflow rooted in human large-scale genetic studies to identify putative candidate genes and affected cells associated with cardiovascular traits. Collectively, our workflow allows for the identification of cell-specific targets relevant for atherosclerosis and can be universally applied to other complex genetic diseases and traits.
Translational perspective GWAS identified a large number of genomic loci associated with atherosclerotic disease. The translation of these results into drug development and faster diagnostics remains challenging. With our approach, we cross-reference the GWAS findings for atherosclerotic disease with scRNA-seq data of disease-relevant tissue and bring the GWAS findings closer to the functional and mechanistic studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from: Fondation Leducq ['PlaqOmics' 18CVD02 to G.P. and C.L.M.], the National Institutes of Health [R01HL148239 and R00HL125912 to C.L.M], the Netherlands CardioVascular Research Initiative of the Netherlands Heart Foundation [CVON 2011/B019 and CVON 2017-20 supporting S.W.v.d.L], Generating the best evidence-based pharmaceutical targets for atherosclerosis [GENIUS I&II supporting S.W.v.d.L], Interuniversity Cardiology Institute of the Netherlands [ICIN, 09.001] supporting S.W.v.d.L], American Heart Association Transformational Project Award [19TPA34910021 supporting R.A. and M.C.].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Athero-Express Biobank Study was approved by the Medical Ethical Committee of the University Medical Centre Utrecht
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared last authorship
Data Availability
Custom scripts used for this publication are available on GitHub https://github.com/CirculatoryHealth/gwas2single. Raw summary statistics can be accessed through their original publications (Supplemental Table 4). Quality controlled and/or FUMA-MAGMA processed summary statistics are available for download at Zenodo (https://zenodo.org/record/4823040). Raw human carotid artery plaque scRNAseq data can be accessed via https://dataverse.nl/dataverse/atheroexpress. The plaque scRNAseq data after quality control, i.e. counts, scores, etc., used in this paper can be found at https://doi.org/10.34894/TYHGEF. Other data supplements can be found in the Supplementary Data section.
https://zenodo.org/record/4823040
